Innovations in Spatial Transcriptomics with MGI

Introduction

Cutting-edge spatial transcriptomics has become essential for understanding tissue architecture and gene expression in the context of disease. Professor Christian Conrad at Charité, one of Europe’s largest university hospitals, highlights the transformative impact of MGI’s innovative platforms—Stereo-seq, FluoXpert, and αLab—on translational research and patient care. His perspective underscores the need for open APIs to foster collaboration, support artificial intelligence (AI) solutions, and ultimately accelerate discoveries in biology and medicine.

Stereo-seq: Leading the Way in Spatial Transcriptomics

Professor Conrad regards MGI’s Stereo-seq (spatial transcriptomics) as “the best I know in the moment” when it comes to in situ capture-based methods. While alternative spatial approaches exist—like in situ sequencing—Stereo-seq stands out for its accuracy, efficiency, and ability to capture a comprehensive view of gene expression within intact tissue sections.

1. High-Resolution Mapping: Stereo-seq allows researchers to visualize and quantify transcriptional landscapes without compromising tissue integrity.

2. Clinical Relevance: From tumor microenvironments to developmental biology, the potential applications of this technology are enormous.

3. Integration with Other Platforms: Combining Stereo-seq with standard Next-Generation Sequencing (NGS) approaches can provide a holistic picture of gene regulation and cellular behavior.

“Stereo-seq is definitely the best I know at the moment for in situ capture.”
— Professor Christian Conrad

FluoXpert: Merging Imaging and Sequencing

Equally exciting is FluoXpert, which merges advanced imaging with molecular sequencing in a single, streamlined system. Professor Conrad emphasizes that having both functionalities in one platform is a major leap forward for the research community:

• Parallel Analysis: Capture morphological data (imaging) alongside genomic or transcriptomic data (sequencing) for immediate correlation.

• Reduced Complexity: Eliminates the need to toggle between separate instruments, saving time and resources in a busy lab environment.

• Potential for Automation: Seamless integration primes FluoXpert for automated workflows, crucial for large-scale studies and personalized medicine initiatives.

“The most exciting and thrilling products for me at MGI are the FluoXpert… you would just need one system.”
— Professor Christian Conrad

αLab: Customizable Experimental Workflows

Research often demands flexibility, particularly in translational environments. Professor Conrad lauds αLab as a “very exciting” innovation that enables users to configure different scenarios within a single platform:

• Modular Design: Researchers can adapt the system to specific projects, whether it involves high-throughput sample prep, automation, or specialized protocols.

• Scalability: Useful for labs with evolving needs—start small and expand the system’s capabilities as new projects emerge.

• Reduced Footprint: Instead of multiple devices, a single platform can address diverse experimental pipelines.

“I think the right direction is to let people really configure their own systems in one device.”
— Professor Christian Conrad

The Call for Open APIs

A major pillar in Professor Conrad’s vision for the future is the availability of open software interfaces or APIs. By facilitating AI-driven development and customization, MGI would empower researchers to build upon existing technology:

• Collaboration & Innovation: Open APIs enable a broader community of developers and scientists to create specialized analysis pipelines.

• Rapid Progress: Lab-specific solutions can be integrated quickly, avoiding the wait for one-size-fits-all software updates.

• Patient Benefits: Tailored solutions foster faster discoveries and more accurate diagnoses, ultimately benefiting patient care.

“I would hope MGI would be smart enough to let people develop their own software for these systems… beneficial for everybody.”
— Professor Christian Conrad

Conclusion

From Stereo-seq’s pioneering role in spatial transcriptomics to FluoXpert’s combined imaging and sequencing capabilities, MGI’s product suite offers transformative tools for modern biomedical research. Professor Christian Conrad underscores the potential impact on patient outcomes, noting that customizable, integrated, and open-API systems pave the way for AI-driven breakthroughs. Ultimately, this synergy of technology, flexibility, and collaboration positions MGI at the forefront of next-generation healthcare solutions.